CPT® Code 81445

Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis

The CPT® Code 81445 pertains to a genomic sequence analysis panel specifically designed for solid organ neoplasms. This panel involves the molecular genetic testing of a tumor sample to identify sequence variants and copy number variants across a range of 5 to 50 genes. The genes included in this analysis may encompass critical oncogenes and tumor suppressor genes such as ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, and RET. The primary objective of this testing is to provide insights into the genetic alterations present in the tumor, which can significantly influence treatment decisions following a cancer diagnosis. By understanding the molecular characteristics of the tumor, healthcare providers can tailor treatment strategies that are more likely to be effective based on the specific genetic pathways involved. The testing process may involve various methodologies, including next-generation sequencing, immunohistochemistry, fluorescence in situ hybridization (FISH), pyrosequencing, quantitative PCR, and DNA/RNA fragment analysis. These advanced techniques enable the detection of a wide array of mutations, such as base substitutions, duplications, deletions, and rearrangements, thereby enhancing the precision of cancer treatment.